JBIO Jade Biosciences, Inc. Common Stock

XNAS 15.13 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

JBIO $15.13 —
Key stats
$15.13
52-Week Range
$8.36 – $28.00
YTD
+6.85%
IV Rank (30D)
91.38
Straddle Price
$5.05
P/C Vol Ratio
0.02
Market Cap
$0.9B
Open
$14.84
Day Range
$14.72 – $15.43
Volume
931,929
Prev Close
$14.86
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY1.13
Cost of Equity (CAPM)11.36% (VRP-adj)
WACC11.30%
Volatility Risk Premium+92.4pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-28.0%
Book / Price62.2% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$17.71 (Market Anchor value)
SMA 20 / Bollinger Mid$14.07
Bollinger Width / SMA2095.5% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
90%
20-Day Fair Value
≈ by Nov 20, 2026
$15.15
α +0.1% rank 78%
conviction
10%
40-Day Fair Value
≈ by Dec 21, 2026
$15.66
α +3.5% rank 82%
conviction
91%
60-Day Fair Value
≈ by Jan 19, 2027
$15.72
α +3.9% rank 81%
conviction
90%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.6× · 3 peers
Peer EV/EBITDA n/a 0% median 19.0× · 3 peers
Peer P/B $32.68 15% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.8× · 3 peers
Market Anchor (SMA50) $17.71 62% stability 82% (BB-width)
Options Expected (B-L 30d) $14.50 23% 12 strikes · skew +0.52
As of 2026-10-22 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.9B
Employees
55
List Date
2025-04-29
CIK
0001798749
Next Earnings
2026-11-12 (Pre-Market)
EPS Forecast
($0.73) (5 est.)
Headquarters
Waltham, MA
Homepage
https://www.jadebiosciences.com

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'25'26Avg
Jan--10.24%10.24%
Feb---10.93%-10.93%
Mar---0.50%-0.50%
Apr-6.31%52.31%23.00%
May-27.50%-13.17%-20.34%
Jun38.75%19.53%29.14%
Jul-33.70%-8.86%-21.28%
Aug14.66%11.54%13.10%
Sep13.25%-33.16%-9.95%
Oct7.57%9.88%*8.73%
Nov35.37%--35.37%
Dec27.52%--27.52%
Total50.67%15.31%32.99%
* Only 2 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $14.07
SMA 50: $17.71
SMA 200: $18.21
Current: $15.13
EMA 12: $14.26
EMA 26: $15.09
MACD: -0.8302 | Signal: 0.3478
BEARISH
ADX (14): 37.96
TREND
+DI: 19.90
−DI: 23.69

Momentum Oscillators

RSI (14): 49.66
NEUTRAL
Stoch %K: 77.92
Stoch %D: 59.91
Williams %R: -11.61

Volume & Volatility

BB Upper: $15.01
BB Lower: $13.12
OVERBOUGHT
OBV: 258,534
Vol SMA 20: 944,615
Vol ROC: -2.03%
ATR: $0.96
True Range: $0.71
HV 20: 45.3%
HV 30: 59.4%
HV 60: 57.9%

Data Summary

Data Points: 373
Last Updated:
Date Range: 2025-04-29T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 8/10)

Key Drivers:

  • Positive recent news headlines, particularly regarding the company's clinical trials and corporate appointments
  • Technical indicators such as MACD and RSI indicating potential uptrend momentum

Primary Risks:

  • High volatility relative to market, increasing risk of large price movements
  • Options market pricing a significant move by expiration, potentially leading to increased volatility

Investment Thesis: JBIO has strong technical momentum and positive recent news sentiment, suggesting a potential long-term uptrend. However, the high volatility and options market pricing suggest caution is warranted.

Recent News Sentiment Impact:

The recent news headlines have been overwhelmingly positive, with the appointment of Mark Eisner, M.D., to the board of directors and positive interim phase 1 results for JADE101. These developments have likely contributed to the stock's upward momentum.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - Uptrend; Medium-term (1-3 months) - Uptrend; Long-term (3-12 months) - Bullish Momentum

Support/Resistance Levels:

  • Upper Bollinger Band: $24.47
  • Middle Bollinger Band: $22.06
  • Lower Bollinger Band: $19.65
  • 20-day SMA: $22.06
  • 50-day SMA: $21.33
  • 200-day SMA: $17.76

Momentum Signals:

  • RSI (14): 46.28 (neutral)
  • MACD: 0.11 / Signal: -0.24 / Histogram: 0.35 (bullish momentum)

Volume Analysis:

  • Volume SMA 20: 764817.56
  • On-Balance Volume (OBV): 6228543.75
  • Volume Rate of Change: -94.53%

News & Sentiment Analysis

Recent Headlines Summary: The past week has seen a series of positive news headlines, including the appointment of Mark Eisner, M.D., to the board of directors and positive interim phase 1 results for JADE101.

Sentiment Assessment: Aggregate sentiment is POSITIVE (70% positive, 30% neutral)

Catalyst Identification:

  • Upcoming clinical trial data releases
  • Regulatory approvals or setbacks

Market Narrative: The recent news headlines have been overwhelmingly positive, suggesting a potential long-term uptrend. However, the high volatility and options market pricing suggest caution is warranted.

Risk & Volatility Assessment

Risk Assessment:

  • Beta: 1.36 (vs SPY) - High risk relative to market
  • Alpha: 0.98 - Above-average return relative to market
  • Correlation: 0.24 - Low correlation with market, increasing risk

Volatility Regime: Current volatility levels are HIGH compared to historical norms.

Options Market Signals:

  • IV Rank: 9.5% (Low) - shows if volatility is historically high/low
  • Current IV: 115.1%
  • Expected Move: $3.05 (21 DTE), 7-DTE: $3.05
  • Volume Flow: 1 calls vs 100 puts
  • Open Interest: 1 calls vs 224 puts
  • Put/Call Volume Ratio: 100.00 (Bearish sentiment)
  • Put/Call OI Ratio: 224.00

Downside Protection:

  • Support levels: $19.65 (Lower Bollinger Band) and $17.76 (200-day SMA)

Market Context & Positioning

Sector Performance:

  • Relative strength vs sector/market: JBIO is outperforming the market in the biotech sector.

Institutional Activity:

  • Volume patterns suggesting institutional interest: The recent increase in volume suggests institutional buying interest.

Correlation Analysis:

  • How stock moves relative to market (R-squared interpretation): 0.24 - Low correlation with market, increasing risk

Relative Valuation:

  • Position within trading range: JBIO is currently trading near the upper end of its recent trading range, suggesting potential for a pullback or consolidation.

Key Levels & Action Items

Critical Price Levels:

  • Support levels: $19.65 (Lower Bollinger Band) and $17.76 (200-day SMA)
  • Resistance levels: $24.47 (Upper Bollinger Band)

Breakout/Breakdown Levels:

  • Breakout level: $25.00 (Above Upper Bollinger Band)
  • Breakdown level: $18.00 (Below Lower Bollinger Band)

Time-Sensitive Catalysts:

  • Upcoming clinical trial data releases
  • Regulatory approvals or setbacks

Risk Management:

  • Stop-loss levels: $20.50 and $19.90
  • Position sizing considerations: 5-10% of portfolio size

Please note that this report is based on the provided data and should not be considered investment advice. It is essential to evaluate the risks and potential rewards associated with any stock or investment before making a decision.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
46.32%
Avg Actual Move
5.48%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-01 Pre-Market 60.26% 5.26% 0.09x Within
2025-08-13 After-Close 136.43% 7.64% 0.06x Within
2025-11-14 After-Close 31.31% 17.66% 0.56x Within
2026-01-05 After-Close 22.87% 0.38% 0.02x Within
2026-03-06 After-Close 34.88% 2.70% 0.08x Within
2026-05-08 After-Close 16.18% 3.68% 0.23x Within
2026-08-10 Pre-Market 22.31% 1.05% 0.05x Within

Earnings calendar: this week’s reports with expected vs actual moves →

JBIO Options Activity & IV Rank

JBIO IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 144.0%
7-DTE IV: —
Expected Move: $5.05
7-DTE Move: $5.05
Days to Exp: 30 (2026-11-20)

Options Flow

Call Volume: 676
Put Volume: 12
P/C Volume: 0.018
BULLISH
Call OI: 636
Put OI: 10
P/C OI: 0.016
Total OI: 646

ATM Options Pricing

ATM Call: $2.55
ATM Put: $2.50
Call %: 16.9%
Put %: 16.5%

Chain Summary

Chain Volume: 791
Chain OI: 2,391
Last Updated: 10/21/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 9th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
9%
vs own history
GEX tilt
-0.90
OI-weighted, today
Vanna tilt
-0.95
δ-sensitivity to IV
Charm tilt
+0.96
δ-decay vs time
Vanna tilt -0.95: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.96: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 21 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 21 · ATM 148.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)91.4HighOct 21
Straddle Price (30 DTE)$5.05Oct 21
Beta Analysis

Risk Metrics

Beta: 1.2596
Alpha: 48.26%
Correlation: 0.2211
R-Squared: 4.9%
Stock Volatility: 72.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own JBIO
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$20.7M
0.01%
#1129 of 6285+577.3%13F
Millennium Management Hedge fund
Izzy Englander
$7.0M
0.00%
#1833 of 3716+96.5%13F
Point72 Hedge fund
Steve Cohen
$3.7M
0.01%
#1082 of 1945-36.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$1.6M
0.00%
#2078 of 3138-45.5%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

JBIO Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 46,710,896 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

156 filers78,104,546 shares$1.70B value167.21% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 9,126,877 $202.80M 11.96% 19.54% 2026-06-30
2 Jupiter Topco LLC 6,273,262 $139.37M 8.22% 13.43% 2026-06-30
3 Fairmount Funds Management LLC 4,553,494 $101.18M 5.97% 9.75% 2026-06-30
4 RA CAPITAL MANAGEMENT, L.P. 3,671,083 $81.57M 4.81% 7.86% 2026-06-30
5 Venrock Adviser, LLC 3,220,364 $71.56M 4.22% 6.89% 2026-06-30
6 Bellevue Group AG 3,057,996 $67.95M 4.01% 6.55% 2026-06-30
7 Paradigm Biocapital Advisors LP 2,857,405 $63.49M 3.75% 6.12% 2026-06-30
8 BlackRock, Inc. Custodian 2,801,451 $62.25M 3.67% 6.00% 2026-06-30
9 Franklin Resources, Inc. Custodian 2,792,080 $62.04M 3.66% 5.98% 2026-06-30
10 State Street Corp 2,335,285 $51.89M 3.06% 5.00% 2026-06-30
11 Vanguard Capital Management LLC 2,244,773 $49.88M 2.94% 4.81% 2026-06-30
12 Janus Henderson Group plc 3,105,669 $43.56M 2.57% 6.65% 2026-03-31
13 ADAGE CAPITAL PARTNERS GP, L.L.C. 1,910,812 $42.46M 2.50% 4.09% 2026-06-30
14 Polar Capital Holdings Plc 1,846,982 $41.04M 2.42% 3.95% 2026-06-30
15 Avidity Partners Management LP 1,700,708 $37.79M 2.23% 3.64% 2026-06-30
16 Remedium Capital Partners, LLC 1,577,750 $35.06M 2.07% 3.38% 2026-06-30
17 Soleus Capital Management, L.P. 1,550,690 $34.46M 2.03% 3.32% 2026-06-30
18 JPMorgan Chase & Co Custodian 1,475,079 $32.61M 1.92% 3.16% 2026-06-30
19 Vanguard Group Inc Custodian 2,095,767 $32.34M 1.91% 4.49% 2025-12-31
20 BAKER BROS. ADVISORS LP 1,230,426 $27.34M 1.61% 2.63% 2026-06-30
21 Logos Global Management LP 1,125,000 $25.00M 1.47% 2.41% 2026-06-30
22 Versant Venture Management, LLC 991,783 $22.04M 1.30% 2.12% 2026-06-30
23 ACORN CAPITAL ADVISORS, LLC 986,760 $21.93M 1.29% 2.11% 2026-06-30
24 Geode Capital Management, LLC Custodian 985,178 $21.90M 1.29% 2.11% 2026-06-30
25 Citadel Advisors LLC Custodian 929,407 $20.65M 1.22% 1.99% 2026-06-30
2 filers$802.14K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $797.70K 99.45% 2026-06-30
2 Simplex Trading, LLC Custodian $4.44K 0.55% 2026-06-30
4 filers$1.95M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $1.52M 78.02% 2026-06-30
2 Simplex Trading, LLC Custodian $415.51K 21.36% 2026-06-30
3 Persistent Asset Partners Ltd $8.86K 0.46% 2026-06-30
4 DIADEMA PARTNERS LP $3.17K 0.16% 2026-06-30

JBIO Insider Trading (Form 4)

Latest: 2026-06-26
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-26 Mark Eisner Director Grant (A) +47,675 opt — EDGAR
2026-06-11 Christopher W. Cain Director Grant (A) +34,843 opt — EDGAR
2026-06-11 Lawrence Otto Klein Director Grant (A) +34,843 opt — EDGAR
2026-06-11 Erin Lavelle Director Grant (A) +34,843 opt — EDGAR
2026-06-11 Eric Dobmeier Director Grant (A) +34,843 opt — EDGAR
2026-06-11 Fairmount Funds Management LLC Director Grant (A) +174,215 opt — EDGAR
2026-02-13 Elizabeth Balta See Remarks Award (A) +28,125 — EDGAR
2026-02-13 Andrew James King See Remarks Award (A) +41,250 — EDGAR
2026-02-13 Tom Frohlich Chief Executive Officer Award (A) +78,750 — EDGAR
2026-02-13 Bradford D. Dahms Chief Financial Officer Award (A) +37,813 — EDGAR
2025-10-08 Fairmount Healthcare Co-Invest IV L.P. Director Award (A) +6,665,630 $9.14 $60.92M EDGAR
2025-07-14 Bradford D. Dahms Chief Financial Officer Grant (A) +526,000 opt — EDGAR
2025-05-19 Tom Frohlich Chief Executive Officer Buy (P) +6,000 $7.40 $44.4K EDGAR
2025-05-01 Erin Lavelle Director Grant (A) +23,017 opt — EDGAR
2025-05-01 Eric Dobmeier Director Grant (A) +23,017 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

JBIO Insider Holdings

6 insiders · @ $15.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Fairmount Healthcare Co-Invest IV L.P. Director 1,897,677 $28.71M $0 1 2025-10-08
2 Andrew James King See Remarks 386,113 $5.84M $0 1 2026-02-13
3 Tom Frohlich Chief Executive Officer 86,331 $1.31M $44.4K 2 2026-02-13
4 Bradford D. Dahms Chief Financial Officer 37,813 $572.1K $0 2 2026-02-13
5 Peter Kolchinsky 10%+ Owner 28,206 $426.8K $0 1 2025-04-30
6 Elizabeth Balta See Remarks 28,125 $425.5K $0 1 2026-02-13
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

JBIO Board & Officers

As of SEC filings through Jun 26, 2026

Directors 11

Officers 5

10% owners 5

Changes in the last 10 years (84)
Jun 25, 2026Mark Eisner became a director
Oct 8, 2025Fairmount Healthcare Co-Invest IV L.P. first on file as a director
Oct 8, 2025Fairmount Healthcare Co-Invest IV L.P. first on file as a 10% owner
Jul 14, 2025Bradford D. Dahms became Chief Financial Officer
Apr 30, 2025Rajeev M. Shah reported in an SEC filing no longer being a director
Apr 30, 2025Rajeev M. Shah reported in an SEC filing no longer being a 10% owner
Apr 30, 2025Ra Capital Management, L.p. reported in an SEC filing no longer being a director
Apr 30, 2025Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner
Apr 30, 2025RA Capital Healthcare Fund LP reported in an SEC filing no longer being a director
Apr 30, 2025RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner
Apr 30, 2025Peter Kolchinsky reported in an SEC filing no longer being a director
Apr 30, 2025Peter Kolchinsky reported in an SEC filing no longer being a 10% owner
Apr 28, 2025Tomas Kiselak became a director
Apr 28, 2025Tomas Kiselak became a 10% owner
Apr 28, 2025Tom Frohlich became a director
Apr 28, 2025Tom Frohlich became Chief Executive Officer
Apr 28, 2025The company announced the departure of Timothy P Noyes from the board in an SEC filing
Apr 28, 2025The company announced the departure of Timothy P Noyes as Chief Executive Officer in an SEC filing
Apr 28, 2025The company announced the departure of Mark T Iwicki from the board in an SEC filing
Apr 28, 2025The company announced the departure of Joshua Resnick from the board in an SEC filing
Not reported recently (13)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

JBIO Proposed Insider Sales (Form 144)

Latest: 2025-06-25
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-06-25 Atlas Venture Fund XII, L.P. Shareholder 28,977 $303.7K 2025-06-25 Merrill Lynch — EDGAR
2025-06-25 Atlas Venture Associates XII, L.P. Shareholder 235 $2.5K 2025-06-25 Merrill Lynch — EDGAR
2025-06-24 Atlas Venture Fund XII, L.P. Shareholder 16,132 $159.2K 2025-06-24 Merrill Lynch — EDGAR
2025-06-24 Atlas Venture Associates XII, L.P. Shareholder 131 $1.3K 2025-06-24 Merrill Lynch — EDGAR
2025-05-06 Atlas Venture Associates XII, L.P. Shareholder 48 $552 2025-05-06 Merrill Lynch — EDGAR
2025-05-06 Atlas Venture Fund XII, L.P. Shareholder 5,883 $67.7K 2025-05-06 Merrill Lynch — EDGAR
2024-06-14 MARINUS VERWIJS Officer 10,600 $265.0K 2024-06-14 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-06-13 HUNTER C GILLIES Officer 6,000 $147.0K 2024-06-13 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-05-17 HUNTER C GILLIES Officer 4,000 $84.3K 2024-05-17 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-05-16 TIMOTHY NOYES Officer, Director 10,000 $215.8K 2024-05-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
37 ETFs hold JBIO
25 shown · $95.28M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.26% $26.6M $10.4B 2026-10-20
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $23.9M — 2026-09-30
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $15.0M $75.1B 2026-10-20
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $8.3M — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.04% $5.5M $13.6B 2026-10-20
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $3.3M — 2026-09-30
7 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.12% $1.8M — 2026-07-31
8 VHT Vanguard Health Care ETF Vanguard 0.01% $1.8M — 2026-09-30
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.15% $1.8M $1.2B 2026-10-20
10 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.09% $1.6M — 2026-10-20
11 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.17% $1.1M — 2026-10-21
12 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.1M $97.4B 2026-10-20
13 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.04% $614,491 — 2026-09-30
14 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $501,778 $10.9B 2026-10-20
15 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.04% $440,629 $1.0B 2026-10-20
16 BBC Virtus Biotech Clinical Trials Etf Nport 0.86% $400,155 — 2026-07-31
17 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $330,397 $3.1B 2026-10-20
18 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $312,996 $3.8B 2026-10-20
19 RSSL Global X Russell 2000 ETF Global X 0.02% $292,463 — 2026-10-21
20 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $225,144 $20.6B 2026-10-20
21 FMED Fidelity Disruptive Medicine ETF Fidelity 0.29% $148,600 $51.7M 2026-10-20
22 MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF Nport 0.01% $72,272 — 2026-05-31
23 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $54,107 — 2026-09-30
24 ISCB iShares Morningstar Small-Cap ETF Nport 0.02% $46,472 — 2026-07-31
25 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Nport 0.01% $40,313 — 2026-05-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.67
TTM Revenue
—
TTM Net Income
$-122.98M
TTM Op. Cash Flow
$-110.02M
Quarterly figures (4 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-46.21M$-0.76$-43.66M
Q1 '262026-03-31—$-33.13M$-0.57$-24.08M
Q3 '252025-09-30—$-19.09M$-0.48$-22.12M
Q2 '252025-06-30—$-24.55M$-0.86$-20.16M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.61
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-28.0%
ROA
-26.0%
Div Yield
0.00%
FCF Yield
-15.57%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$706.74M
as of 2026-10-21
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
12.12M
SI % of Float
33.74%
Days to Cover
11.33
Short Vol Ratio
80.7%
Free Float
35.92M
Float %
72.8%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-05-15